EGFR and non-small cell lung carcinoma: The first test approved by the FDA (cobas EGFR mutation test v2) was aimed at screening patients affected by advanced non-small cell lung cancer (NSCLC) for circulating EGFR mutations, in order to assess their eligibility for erlotinib, an EGFR tyrosine kinase inhibitor [15].